Significantly prolong survival in patients with advanced lung cancer, Keytruda combination therapy is excellent
January 17, 2018 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Today, Merck (MSD) announced positive results in its key phase 3 clinical trial KEYNOTE-189. The trial evaluated the efficacy of the heavy immunotherapy drug Keytruda (pembrolizumab, pemizumab) in combination with pemetrexed (Alimta) and cisplatin or carboplatin in the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC). .
Lung cancer is the leading cause of cancer deaths worldwide. The number of people who die of lung cancer each year exceeds the number of colon, breast and prostate cancers combined. The two main types of lung cancer are NSCLC and small cell lung cancer (SCLC). Among them, NSCLC is the most common type of lung cancer, accounting for about 85% of all cases. The prognosis of patients with advanced metastatic (stage IV) lung cancer is poor, with a 5-year survival rate of only 2%. These patients are in desperate need of new therapies to alleviate the disease.
As an anti-PD-1 therapy, Keytruda can improve the body's ability to detect and fight tumor cells and bring hope to patients with advanced cancer. It is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, and activates T lymphocytes that may affect tumor cells and healthy cells. At present, Keytruda has been approved for the treatment of advanced cancers such as melanoma, NSCLC, head and neck squamous cell carcinoma, classic Hodgkin's lymphoma, urothelial carcinoma, and gastric cancer in many countries.
The KEYNOTE-189, a collaboration between Merck and Eli Lilly, was a randomized, double-blind, placebo-controlled phase 3 study evaluating the efficacy of Keytruda in combination with pemetrexed and platinum-based chemotherapy in patients with NSCLC. 614 patients were randomized to receive either Keytruda+pemetrexed+cisplatin or carboplatin in a 2:1 ratio, or received placebo + pemetrexed plus cisplatin or carboplatin. The results showed that the study reached the dual primary endpoint of overall survival (OS) and progression-free survival (PFS). According to the interim analysis conducted by the Independent Data Monitoring Committee, Keytruda+pemetrexed+platinum chemotherapy significantly prolonged OS and PFS compared to pemetrexed+platinum chemotherapy alone. And Keytruda's security in this combination is consistent with what was previously observed. Specific data will be announced at the upcoming medical conference.
“KEYNOTE-189 shows that using Keytruda in combination with chemotherapy as a first-line therapy can significantly improve overall survival and progression-free survival compared with traditional chemotherapy alone,†said Dr. Roger M. Perlmutter, President of Merck Research Laboratories: “We Many thanks to the patients and researchers involved in KEYNOTE-189 for their important contributions to this landmark study, and we look forward to providing this data in the near future."
We expect this latest result to bring more treatment options to patients.
Reference materials:
[1] Merck's Ace Keytruda Impresses Again, Stuns in Phase III Lung Cancer Trial
[2] Merck Official Website
Raw materials for animal medicine
Conventional veterinary drug raw materials are: oxytetracycline hydrochloride, doxycycline, chlortetracycline hydrochloride, lincomycin sulfate, gentamycin sulfate, tylosin tartrate, florfenicol, water-soluble amoxicillin, sulfamethoxazole, enno Floxacin lactate, ciprofloxacin hydrochloride, ciprofloxacin hydrochloride, metronidazole, ribavirin, vitamin C, astragalus polysaccharide, penicillin potassium.
The traditional Chinese medicine extracts in veterinary medicines are derived from natural Chinese herbal medicines.
It is purified, concentrated and purified in a different ratio from the original drug. It not only retains the natural state and biological activity of the original drug composition structure, but also retains the harmless and
The beneficial exogenous substance essence realizes the micro-quantification and standardization of Chinese herbal medicine raw materials, and provides a new way for the breeding industry to realize green production. The following herbal extracts for veterinary use: Anti-pathogenic microorganisms Chinese medicine: Anything that can inhibit or kill the reproduction of pathogenic microorganisms and improve the immunity of the body is called anti-pathogenic microorganisms
Chinese herbal medicine. According to the theory of traditional Chinese medicine, it can be divided into heat-clearing medicines, exopathic medicines, diarrhea and water-repelling medicines, damp-damping and diuretic medicines, phlegm-relieving and cough-relieving medicines, qi-regulating and Xiao-shi pharmacological blood medicines, and phlegm-relieving and anti-asthmatic medicines.
Raw materials for animal medicine,Nicarbazin in Feeds,Nosiheptide Veterinary,Nosiheptide Antibacterial,Human Gastric Mucin
Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikangbio.com